InsiderSource
BBIO

BridgeBio Pharma, Inc.

SEC CIK 1743881
$66.80 −11.2% · 90 days
90-day buys
$0
0 open-market
90-day sells
$19.38M
41 open-market
Net insider flow
−$19.38M
Net selling
Filings shown
109
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at BBIO have sold a net $19.38M of stock (0 open-market buys vs 41 sells).

Largest recent trade: Ellis Andrea sold $4.21M of BBIO, trimming their stake 78%.

Most active filer: Kumar Neil, with 80 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for BBIO, newest first
View on SEC EDGAR ↗
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −0.1%

Kumar Neil sold $430.8K of BBIO.

−$430.8K
5,960 sh @ $72
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.3%

Kumar Neil sold $162.9K of BBIO.

−$162.9K
2,151 sh @ $76
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.9%

Kumar Neil sold $533.6K of BBIO, trimming their stake 1%.

−$533.6K
6,955 sh @ $77
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −1.4%

Kumar Neil sold $816.4K of BBIO, trimming their stake 1%.

−$816.4K
10,519 sh @ $78
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.1%

Kumar Neil sold $29.3K of BBIO.

−$29.3K
375 sh @ $78
Advertisement
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026

Kumar Neil sold $105.9K of BBIO.

−$105.9K
1,401 sh @ $76
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.1%

Kumar Neil sold $464.3K of BBIO.

−$464.3K
6,067 sh @ $77
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.2%

Kumar Neil sold $827K of BBIO.

−$827K
10,677 sh @ $77
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026

Kumar Neil sold $144.9K of BBIO.

−$144.9K
1,855 sh @ $78
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −1.5%

Kumar Neil sold $848K of BBIO, trimming their stake 2%.

−$848K
11,515 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −1.1%

Kumar Neil sold $601.3K of BBIO, trimming their stake 1%.

−$601.3K
8,085 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.1%

Kumar Neil sold $30.1K of BBIO.

−$30.1K
400 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.3%

Kumar Neil sold $851.8K of BBIO.

−$851.8K
11,565 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −0.2%

Kumar Neil sold $605.1K of BBIO.

−$605.1K
8,135 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Jan 12, 2026

Kumar Neil sold $22.6K of BBIO.

−$22.6K
300 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Dec 16, 2025 ΔOwn −11%

Kumar Neil sold $2.11M of BBIO, trimming their stake 11%.

−$2.11M
28,311 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Dec 16, 2025 ΔOwn −0.7%

Kumar Neil sold $127.9K of BBIO, trimming their stake 1%.

−$127.9K
1,700 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Tax withholding Kumar Neil · Director, Chief Executive Officer · Tax withholding · filed Dec 16, 2025 ΔOwn −11%
−$2.33M
30,964 sh @ $75
Advertisement

About BBIO insider activity

This page tracks every recent Form 4 filed for BridgeBio Pharma, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is BBIO insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for BridgeBio Pharma, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.